Drug patents opposed in 2022
Drug patents opposed in 2022 at the European Patent Office (EPO)
| Patent Number | Patent Title | Company | Recent Opposition Date | Recent Opposition By | Activity Alert |
|---|---|---|---|---|---|
| EP3233108B1 | Rapid-Acting Insulin Compositions | ELI LILLY AND CO |
30 Dec, 2022
(Expiration: Dec, 2035)
|
SCORPIO
| |
| EP3827845B1 | Subcutaneous Formulations Of Anti-Cd38 Antibodies And Their Uses | JANSSEN BIOTECH INC |
29 Dec, 2022
(Expiration: Nov, 2036)
|
STORZ
(and 4 more)
| |
| EP3669853B1 | Compositions For The Preparation Of Fracture-Resistant Dental Workpieces By Means Of Stereolithography | IVOCLAR VIVADENT AG |
28 Dec, 2022
(Expiration: Dec, 2038)
|
ARKEMA FRANCE
| |
| EP4019041B1 | Toxicity Management For Anti-Tumor Activity Of Cars | CHILDRENS HOSPITAL OF PHILADELPHIA CHOP |
28 Dec, 2022
(Expiration: Jul, 2033)
|
BOULT WADE TENNANT
(and 2 more)
| |
| EP3236954B1 | Enteric Film Coating Compositions, Method Of Coating, And Coated Forms | DUPONT NUTRITION USA INC |
23 Dec, 2022
(Expiration: Dec, 2035)
|
ROQUETTE FRRES
| |
| EP3681500B1 | Use Of Pilocarpine Hydrochloride For The Treatment Of Ocular Conditions | ALLERGAN INC |
20 Dec, 2022
(Expiration: Apr, 2039)
|
TEVA PHARMACEUTICAL INDUSTRIES
| |
| EP3309158B1 | Crystalline Form K Of Rivaroxaban And Process For Its Preparation | KRKA TOVARNA ZDRAVIL DD |
15 Dec, 2022
(Expiration: Dec, 2033)
|
BAYER
| |
| EP3518933B1 | Methods Of Treating Uterine Fibroids And Endometriosis | MYOVANT SCIENCES GMBH |
15 Dec, 2022
(Expiration: Sep, 2037)
|
SANDOZ
| |
| EP3793513B1 | Topical Composition | DSM IP ASSETS BV |
14 Dec, 2022
(Expiration: May, 2039)
|
DALLI WERKE
| |
| EP3684475B1 | Hair Dyeing Method | KAO CORP |
14 Dec, 2022
(Expiration: Sep, 2038)
|
LOREAL
| |
| EP3694482B1 | Sulfate Free Personal Cleansing Composition Comprising Low Inorganic Salt | PROCTER AND GAMBLE CO |
13 Dec, 2022
(Expiration: Oct, 2038)
|
DALLI WERKE
(and 6 more)
| |
| EP3438131B1 | Oligosaccharide Modification And Labeling Of Proteins | LIFE TECHNOLOGIES CORP |
13 Dec, 2022
(Expiration: Feb, 2027)
|
HUBER
(and 1 more)
| |
| EP3731801B1 | Compositions For Altering The Color Of Hair | LOREAL SA |
09 Dec, 2022
(Expiration: Dec, 2038)
|
HENKEL
| |
| EP3247711B1 | Novel Salts And Polymorphs Of Scy-078 | SCYNEXIS CHEMISTRY AND AUTOMATION INC |
09 Dec, 2022
(Expiration: Jan, 2036)
|
SYNTHON
| |
| EP2611461B1 | Pegylated Liposomes For Delivery Of Immunogen-Encoding Rna | GLAXOSMITHKLINE BIOLOGICALS SA |
09 Dec, 2022
(Expiration: Aug, 2031)
|
WEICKMANN & WEICKMANN PARTMBB
(and 3 more)
| |
| EP3308774B1 | Hydroxyalkyl Alkyl Cellulose, Method For Producing The Same, And Solid Preparation | SHIN ETSU CHEMICAL CO LTD |
08 Dec, 2022
(Expiration: Oct, 2037)
|
DUPONT NUTRITION BIOSCIENCES APS
| |
| EP3283099B1 | Combination Therapy With Coagulation Factors And Multispecific Antibodies | F HOFFMANN LA ROCHE AG |
02 Dec, 2022
(Expiration: Apr, 2036)
|
MAIWALD
| |
| EP3675811B1 | Keratin Hydrolysate For Oral Cosmetic Use | BRETAGNE CHIMIE FINE SAS |
02 Dec, 2022
(Expiration: Aug, 2038)
|
TESSENDERLO GROUP NVSA
| |
| EP3761948B1 | Sunscreen With A Reduced Tendency To Stain Textiles, Containing Hydrogenated Vegetable Oil And Diethylamino Hydroxybenzoyl Hexyl Benzoate | BEIERSDORF AG |
01 Dec, 2022
(Expiration: Feb, 2039)
|
BASF
| |
| EP3474865B1 | Process For Making Sugammadex | SYNTHON BV |
01 Dec, 2022
(Expiration: Jun, 2037)
|
BOTTI & FERRARI
(and 1 more)
| |
| EP3463276B1 | Process For Treating Hair | KAO GERMANY GMBH |
30 Nov, 2022
(Expiration: Jun, 2037)
|
HENKEL
| |
| EP3309179B1 | Hydroxyalkyl Alkyl Cellulose, Method For Producing The Same, And Solid Preparation | SHIN ETSU CHEMICAL CO LTD |
23 Nov, 2022
(Expiration: Oct, 2037)
|
DUPONT NUTRITION BIOSCIENCES APS
| |
| EP3166976B1 | Anti-Pd-L1 Combinations For Treating Tumors | BIRDIE BIOPHARMACEUTICALS INC CAYMAN ISLANDS |
23 Nov, 2022
(Expiration: Jul, 2035)
|
PATENT BOUTIQUE
| |
| EP2922554B1 | Terminally Modified Rna | MODERNATX INC |
23 Nov, 2022
(Expiration: Oct, 2033)
|
WITHERS & ROGERS
| |
| EP3621596B1 | Nucleic Acid Vector Tablets | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS |
22 Nov, 2022
(Expiration: May, 2038)
|
MEIER
| |
| EP2959894B1 | S1P Receptor Modulators For Treating Multiple Sclerosis | NOVARTIS AG |
21 Nov, 2022
(Expiration: Jun, 2027)
|
A MED
(and 22 more)
| |
| EP3432935B1 | Site-Specific Bio-Conjugation Methods And Compositions Useful For Nanopore Systems | GENIA TECHNOLOGIES INC |
21 Nov, 2022
(Expiration: Mar, 2037)
|
WITHERS & ROGERS
| |
| EP3436439B1 | Process For The Preparation Of Diphenylpyrazine Derivatives | HONOUR (R&D) |
16 Nov, 2022
(Expiration: Apr, 2037)
|
GENERICS UK
| |
| EP3223791B1 | Oral Care Compositions Having High Water Content And Micro Robustness | COLGATE PALMOLIVE CO |
16 Nov, 2022
(Expiration: Dec, 2034)
|
UNILEVER UNILEVER
| |
| EP3777834B1 | Syringe | NOVARTIS AG |
15 Nov, 2022
(Expiration: May, 2033)
|
EHLERS
(and 5 more)
| |
| EP2010220B1 | Stabilized Pentosan Polysulfate (Pps) Formulations And Methods Of Analyzing Them | CEVA ANIMAL HEALTH PTY LTD |
15 Nov, 2022
(Expiration: Apr, 2027)
|
FARMAPATENT STI
| |
| EP3621578B1 | Low Viscosity, High Polyol Self-Foaming Composition | UNILEVER GLOBAL IP LTD |
14 Nov, 2022
(Expiration: May, 2038)
|
HENKEL
| |
| EP3656373B1 | Syringe | NOVARTIS AG |
14 Nov, 2022
(Expiration: Jan, 2033)
|
KEIL & SCHAAFHAUSEN PATENTANWLTE PARTGMBB
(and 2 more)
| |
| EP3461503B9 | Methods Of Administering Tetrahydrobiopterin, Associated Compositions, And Methods Of Measuring | BIOMARIN PHARMACEUTICAL INC |
09 Nov, 2022
(Expiration: Apr, 2028)
|
DIPHARMA
(and 4 more)
| |
| EP3781171B1 | Compounds And Their Uses For Alleviating Menopause-Associated Symptoms | ESTETRA SRL |
09 Nov, 2022
(Expiration: Apr, 2039)
|
ELKINGTON AND FIFE
| |
| EP3487486B1 | Low Cross-Linking Gelatine | ROUSSELOT BV |
09 Nov, 2022
(Expiration: Jul, 2037)
|
GELITA
| |
| EP3316878B1 | Methods And Compounds For The Alleviation And/Or Prevention Of Bone Loss | INDIVIDUAL |
09 Nov, 2022
(Expiration: Jun, 2036)
|
J A KEMP
| |
| EP3240529B1 | Stable Pharmaceutical Compositions Comprising Micafungin | GALENICUM HEALTH SL |
31 Oct, 2022
(Expiration: Dec, 2035)
|
STRAWMAN
(and 1 more)
| |
| EP3121169B1 | Methods Of Synthesis And/Or Purification Of Diaminophenothiazinium Compounds | WISTA LABORATORIES LTD |
27 Oct, 2022
(Expiration: Jul, 2027)
|
PROVEPHARM LIFE SOLUTIONSPROVEPHARM
| |
| EP3525799B1 | Method For Establishing, Restoring, And Preserving Homeostasis Of The Ocular Surface | ICOM MEDICAL GMBH |
26 Oct, 2022
(Expiration: Oct, 2037)
|
BAUSCH LOMB IRELAND
| |
| EP3368071B1 | Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic Effect | REVANCE THERAPEUTICALS INC |
26 Oct, 2022
(Expiration: Oct, 2036)
|
IPSEN BIOPHARMA
| |
| EP3574901B1 | Injection Devices Comprising A Composition Of Hyaluronic Acid And Mepivacaine Hydrochloride | TEOXANE SA |
26 Oct, 2022
(Expiration: Jul, 2034)
|
LABORATOIRES VIVACY
| |
| EP3578173B1 | Dosage Form Containing Oxycodone And Naloxone | EURO CELTIQUE SA |
26 Oct, 2022
(Expiration: Feb, 2026)
|
SANDOZ
(and 4 more)
| |
| EP3714877B1 | Method And Composition For Treating Ocular Hypertension And Glaucoma | ASAHI GLASS CO LTD |
25 Oct, 2022
(Expiration: May, 2029)
|
COOKE
(and 2 more)
| |
| EP3727279B1 | Oil-In-Water Emulsified Cosmetic | LVMH RECHERCHE GIE |
25 Oct, 2022
(Expiration: Dec, 2037)
|
HENKEL
| |
| EP2658541B1 | Topical Localized Isoxazoline Formulation Comprising Glycofurol | INTERVET INTERNATIONAL BV |
25 Oct, 2022
(Expiration: Dec, 2031)
|
VIRBAC
| |
| EP2658542B1 | Topical Localized Isoxazoline Formulation | INTERVET INTERNATIONAL BV |
25 Oct, 2022
(Expiration: Dec, 2031)
|
VIRBAC
| |
| EP3113774B1 | Compositions Of Grapiprant And Methods For Using The Same | ELANCO ANIMAL HEALTH INC |
25 Oct, 2022
(Expiration: Mar, 2035)
|
VIRBAC
(and 1 more)
| |
| EP2359858B1 | Nutritional Composition Comprising Indigestible Oligosaccharides | NUTRICIA NV |
24 Oct, 2022
(Expiration: Aug, 2025)
|
NESTL HEALTH SCIENCE DEUTSCHLAND NESTL NUTRITION
(and 1 more)
| |
| EP3256125B1 | Dosing Regimen For A Selective S1P1 Receptor Agonist | ACTELION PHARMACEUTICALS LTD |
21 Oct, 2022
(Expiration: Dec, 2035)
|
TEVA PHARMACEUTICAL INDUSTRIES
(and 1 more)
| |
| EP3613794B1 | Cellulose Acetate Particles, Cosmetic Composition, And Cellulose Acetate Particle Production Method | DAICEL CORP |
19 Oct, 2022
(Expiration: Feb, 2039)
|
CERDIA
| |
| EP3431074B1 | Preservative Free Bimatoprost And Timolol Solutions | ALLERGAN INC |
19 Oct, 2022
(Expiration: Jul, 2031)
|
SIFI
(and 6 more)
| |
| EP2988750B1 | Use Of Landiolol Hydrochloride In The Long-Term Treatment Of Tachyarrhythmias | AOP ORPHAN PHARMACEUTICALS AG |
18 Oct, 2022
(Expiration: Apr, 2034)
|
BECKER
| |
| EP2790531B1 | Cohesive Thin Liquids To Promote Safe Swallowing In Dysphagic Patients | SOCIETE DES PRODUITS NESTLE SA |
18 Oct, 2022
(Expiration: Dec, 2032)
|
FRESENIUS KABI DEUTSCHLAND
(and 1 more)
| |
| EP3636778B1 | Agents For Use In Treating Facioscapulohumeral Dystrophy (Fshd) | LEIDS UNIVERSITAIR MEDISCH CENTRUM LUMC |
12 Oct, 2022
(Expiration: Aug, 2031)
|
CMS CAMERON MCKENNA NABARRO OLSWANG
(and 1 more)
| |
| EP2986304B1 | Pharmaceutical Composition, Methods For Treating And Uses Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
12 Oct, 2022
(Expiration: Apr, 2034)
|
KRAUS & WEISERT PATENTANWLTE PARTGMBB
(and 3 more)
| |
| EP3632448B1 | Pharmaceutical Composition Comprising Drospirenone And Contraceptive Kit | LABORATORIOS LEON FARMA SA |
12 Oct, 2022
(Expiration: Jun, 2031)
|
LUIGI
(and 1 more)
| |
| EP3138566B1 | Treatment Of Phenylketonuria With Bh4 | BIOMARIN PHARMACEUTICAL INC |
12 Oct, 2022
(Expiration: Nov, 2024)
|
TOBIO NOVELFARMA ILAC SAN VE TIC A S
(and 2 more)
| |
| EP3692101B1 | Brilliant Blue (Bbg) Dye Derivatives And Staining Compositions Comprising The Same For Selectively Staining Biological Substrates | ALFA INSTRUMENTS SRL |
11 Oct, 2022
(Expiration: Oct, 2038)
|
DORC DUTCH OPHTHALMIC RESEARCH CENTER
| |
| EP3300601B1 | Fixed Drug Ratios For Treatment Of Hematopoietic Cancers And Proliferative Disorders | ROTALEC IP HOLDINGS LLC |
11 Oct, 2022
(Expiration: Feb, 2028)
|
SANDOZ
(and 2 more)
| |
| EP3403646B1 | Liquid Pharmaceutical Composition | FRESENIUS KABI DEUTSCHLAND GMBH |
05 Oct, 2022
(Expiration: May, 2035)
|
BIOGEN
(and 1 more)
| |
| EP3230316B1 | Treatment Of Age Related Macular Degeneration With A Small Active Choroidal Neovascularization Lesion | BAYER HEALTHCARE LLC |
05 Oct, 2022
(Expiration: Dec, 2035)
|
BOULT WADE TENNANT
(and 5 more)
| |
| EP3840867B1 | Methods, Devices, Systems And Kits For Preparing Compositions For Care And Repair Of Varicose Veins | VASCULAR BARCELONA DEVICES SL |
05 Oct, 2022
(Expiration: Aug, 2039)
|
KOCH
| |
| EP3256097B1 | Compositions And Methods For Improving Skin Appearance | ALLERGAN INDUSTRIE SAS |
05 Oct, 2022
(Expiration: Feb, 2036)
|
MERZ PHARMA
(and 1 more)
| |
| EP2833908B1 | Mycoplasma Hyopneumoniae Vaccine | ZOETIS SERVICES LLC |
03 Oct, 2022
(Expiration: Apr, 2033)
|
BOEHRINGER INGELHEIM VETMEDICA
| |
| EP2774483B1 | Composition Containing Sorbitan Monocaprylate And A Selected Pyridone | CLARIANT INTERNATIONAL LTD |
30 Sep, 2022
(Expiration: May, 2030)
|
KAO GERMANY
| |
| EP3995135B1 | Prolonged Release Dosage Form Of Tapentadol L-(+)- Tartaric Acid Salt | GRUENENTHAL GMBH |
30 Sep, 2022
(Expiration: Nov, 2040)
|
SANDOZ
(and 1 more)
| |
| EP3283125B1 | Lyophilization Of Rna | CUREVAC REAL STATE GMBH |
29 Sep, 2022
(Expiration: Apr, 2036)
|
SANOFI
(and 1 more)
| |
| EP2914229B1 | Easy Access Bandages, Packaging, And Systems For Application | GENUINE FIRST AID INTERNATIONAL LTD |
27 Sep, 2022
(Expiration: Oct, 2033)
|
ORKLA WOUND CARE
| |
| EP3718565B1 | Respiratory Virus Vaccines | MODERNATX INC |
23 Sep, 2022
(Expiration: Oct, 2036)
|
BIONTECH
(and 3 more)
| |
| EP3536311B1 | Storage Stable Composition Comprising Rifaximin Alpha | SANDOZ AG |
22 Sep, 2022
(Expiration: Mar, 2037)
|
ALFASIGMA
| |
| EP3394030B1 | Compounds And Compositions For Intracellular Delivery Of Agents | MODERNATX INC |
22 Sep, 2022
(Expiration: Dec, 2036)
|
BOULT WADE TENNANT
| |
| EP3443969B1 | Brain Function-Improving Composition For Newborns | MEIJI CO LTD |
22 Sep, 2022
(Expiration: Apr, 2037)
|
FRIESLANDCAMPINA NEDERLAND
(and 1 more)
| |
| EP3433276B1 | Early Intervention Methods To Prevent Or Ameliorate Toxicity | SEATTLE CHILDRENS HOSPITAL |
22 Sep, 2022
(Expiration: Mar, 2037)
|
GILL JENNINGS & EVERY
(and 3 more)
| |
| EP3763820B1 | Retroviral Transduction Using Poloxamers | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH |
22 Sep, 2022
(Expiration: Feb, 2033)
|
KNIG SZYNKA TILMANN VON RENESSE
| |
| EP3039040B1 | Anti Cd30 Chimeric Antigen Receptor And Its Use | INDIVIDUAL |
22 Sep, 2022
(Expiration: Aug, 2034)
|
MARGARET DIXON
| |
| EP3134131B1 | Nucleic Acid Vaccines | MODERNATX INC |
22 Sep, 2022
(Expiration: Apr, 2035)
|
PFIZER
(and 4 more)
| |
| EP3737765B1 | Enhanced Immune Cells Using Dual Shrna And Composition Including The Same | CUROCELL INC |
21 Sep, 2022
(Expiration: Jan, 2039)
|
ELKINGTON AND FIFE
| |
| EP3560500B1 | Progesterone Formulations | THERAPEUTICSMD INC |
21 Sep, 2022
(Expiration: Jun, 2033)
|
RIECK
(and 1 more)
| |
| EP3630726B1 | Crystalline Solid Forms Of Salts Of N-{4-[(6,7-Dimethoxyquinolin-4-Yl) Oxy]Phenyl}-N'-(4-Fluorphenyl) Cyclopropane-1,1-Dicarboxamide, Processes For Making, And Methods Of Use | EXELIXIS INC |
21 Sep, 2022
(Expiration: May, 2038)
|
STADA ARZNEIMITTEL
| |
| EP2806900B1 | Rna Modulating Oligonucleotides With Improved Characteristics For The Treatment Of Duchenne And Becker Muscular Dystrophy | BIOMARIN TECHNOLOGIES BV |
15 Sep, 2022
(Expiration: Jan, 2033)
|
STRAWMAN
(and 1 more)
| |
| EP3291679B1 | Altering Microbial Populations & Modifying Microbiota | SNIPR TECHNOLOGIES LTD |
14 Sep, 2022
(Expiration: May, 2036)
|
ELIGO BIOSCIENCE
(and 2 more)
| |
| EP3010355B1 | Method For Treating A Swallowing Disorder | SOCIETE DES PRODUITS NESTLE SA |
14 Sep, 2022
(Expiration: May, 2034)
|
FRESENIUS KABI DEUTSCHLAND
| |
| EP2986312B1 | Cytokine Derived Treatment With Reduced Vascular Leak Syndrome | INSTITUT GUSTAVE ROUSSY (IGR) |
14 Sep, 2022
(Expiration: Apr, 2034)
|
WUESTHOFF & WUESTHOFF PATENTANWLTE PARTG MBB
(and 1 more)
| |
| EP3397378B1 | Microcapsule Comprising A Membrane Obtained By Microencapsulation Using Complex Coacervation, And Obtention Method | CAPSULAE SAS |
13 Sep, 2022
(Expiration: Dec, 2036)
|
FIRMENICH
| |
| EP3175863B1 | Variants Of C-Type Natriuretic Peptide | BIOMARIN PHARMACEUTICAL INC |
01 Sep, 2022
(Expiration: May, 2030)
|
ASCENDIS PHARMA GROWTH DISORDERS
| |
| EP3574914B1 | Corticosteroid Compositions | VIROPHARMA BIOLOGICS LLC |
01 Sep, 2022
(Expiration: Nov, 2028)
|
DR FALK PHARMA
| |
| EP3682905B1 | Modified Nucleosides, Nucleotides, And Nucleic Acids, And Uses Thereof | MODERNATX INC |
01 Sep, 2022
(Expiration: Oct, 2032)
|
MAIWALD PATENT UND RECHTSANWALTSGESELLSCHAFT
(and 9 more)
| |
| EP3463308B1 | Formulations Of Polyalkylene Oxide-Asparaginase And Methods Of Making And Using The Same | SERVIER IP UK LTD |
31 Aug, 2022
(Expiration: Jun, 2037)
|
STRAWMAN
| |
| EP3138853B1 | Fc Variants With Altered Binding To Fcrn | XENCOR INC |
24 Aug, 2022
(Expiration: Sep, 2028)
|
COHAUSZ & FLORACK PATENT UND RECHTSANWLTE PARTNERSCHAFTSGESELLSCHAFT MBB
| |
| EP3157571B1 | Fatty Acids And Their Use In Conjugation To Biomolecules | NOVARTIS AG |
24 Aug, 2022
(Expiration: Jun, 2035)
|
DR H ULRICH DRRIES
| |
| EP3209783B1 | Permanent Epigenetic Gene Silencing | FONDAZIONE TELETHON |
24 Aug, 2022
(Expiration: Oct, 2035)
|
JAMES POOLE
(and 1 more)
| |
| EP2851361B1 | Highly Unsaturated Fatty Acid Or Highly Unsaturated Fatty Acid Ethyl Ester With Reduced Environmental Pollutants, And Method For Producing Same | NIPPON SUISAN KAISHA LTD |
24 Aug, 2022
(Expiration: May, 2033)
|
KD PHARMA BEXBACH
| |
| EP3115064B1 | Rna-Coded Antibody | CUREVAC AG |
24 Aug, 2022
(Expiration: Jan, 2028)
|
MODERNA THERAPEUTICS
| |
| EP3095447B1 | Treating Vitamin D Insufficiency And Deficiency With 25-Hydroxyvitamin D2 And 25-Hydroxyvitamin D3 | OPKO RENAL LLC |
23 Aug, 2022
(Expiration: Feb, 2027)
|
DSM NUTRITIONAL PRODUCTS
| |
| EP3324937B1 | Ready-To-Use Bortezomib Solution | STADA ARZNEIMITTEL AG |
18 Aug, 2022
(Expiration: Jul, 2036)
|
EVER VALINJECT
(and 6 more)
| |
| EP3811927B8 | A Stable Parenteral Dosage Form Of Cetrorelix Acetate | SUN PHARMACEUTICAL INDUSTRIES LTD |
12 Aug, 2022
(Expiration: Mar, 2040)
|
WEICKMANN & WEICKMANN PARTMBB
| |
| EP3603679B1 | Rna-Guideded Transcriptional Regulation | HARVARD COLLEGE |
11 Aug, 2022
(Expiration: Jun, 2034)
|
CRISPR THERAPEUTICS
| |
| EP3253382B1 | Pharmaceutical Compositions For Combination Therapy | INTERCEPT PHARMACEUTICALS INC |
11 Aug, 2022
(Expiration: Feb, 2036)
|
STADA ARZNEIMITTEL
| |
| EP3347102B1 | Process For Permanent Shaping Hair | KAO GERMANY GMBH |
10 Aug, 2022
(Expiration: Mar, 2036)
|
LOREAL
| |
| EP3283044B1 | Surface Treating Conditioning Composition | PROCTER AND GAMBLE CO |
10 Aug, 2022
(Expiration: Apr, 2036)
|
UNILEVER UNILEVER UNILEVER
| |
| EP3397252B1 | Personal Care Compositions | COLGATE PALMOLIVE CO |
09 Aug, 2022
(Expiration: Dec, 2035)
|
HENKEL
(and 2 more)
| |
| EP3548000B1 | Atropine Pharmaceutical Compositions | VYLUMA INC |
09 Aug, 2022
(Expiration: May, 2038)
|
PHARMA STULLN
| |
| EP3162359B1 | Oil-In-Water Emulsion Composition | SHISEIDO CO LTD |
03 Aug, 2022
(Expiration: Jun, 2035)
|
HENKEL
| |
| EP3191461B1 | Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole | PFIZER INC |
03 Aug, 2022
(Expiration: Aug, 2035)
|
HOLLATZ
(and 4 more)
| |
| EP3117827B1 | Composition For Vagina And Use Of The Composition | SINGAPORE ZE&Z INTERNATIONAL PTE LTD |
03 Aug, 2022
(Expiration: Mar, 2035)
|
KIMBERLY CLARK WORLDWIDE
| |
| EP2459555B1 | Processes For Crystallization Of Rivaroxaban | KRKA DD |
02 Aug, 2022
(Expiration: Jul, 2030)
|
DR SCHN
| |
| EP3222272B1 | Pharmaceutical Composition | FERRING BV |
01 Aug, 2022
(Expiration: Sep, 2031)
|
EVER VALINJECT
| |
| EP2673262B1 | Processes For Preparing Quinoline Compounds And Pharmaceutical Compositions Containing Such Compounds | EXELIXIS INC |
01 Aug, 2022
(Expiration: Feb, 2032)
|
STADA ARZNEIMITTEL
| |
| EP3685826B1 | Syringe | NOVARTIS AG |
29 Jul, 2022
(Expiration: Jan, 2033)
|
WITHERS & ROGERS
(and 5 more)
| |
| EP3459554B1 | Yeast Extract Having Diabetes Prevention Effect | KOHJIN LIFE SCIENCES CO LTD |
27 Jul, 2022
(Expiration: May, 2037)
|
STEINBACH
| |
| EP3116529B1 | Interleukin-2 For Treating Food Allergy | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS |
27 Jul, 2022
(Expiration: Mar, 2035)
|
STRAWMAN
| |
| EP3481507B1 | Cosmetic Composition Comprising A Particular Combination Of Surfactants, A Silicone, A Cationic Polymer, A Fatty Alcohol And A Clay | LOREAL SA |
26 Jul, 2022
(Expiration: Jul, 2037)
|
HENKEL
| |
| EP2922526B1 | Manufacturing Of Semi-Plastic Pharmaceutical Dosage Units | INTERVET INTERNATIONAL BV |
26 Jul, 2022
(Expiration: Nov, 2033)
|
KRKA
| |
| EP2574331B1 | Method For Colouring Hair | WELLA OPERATIONS US LLC |
26 Jul, 2022
(Expiration: Sep, 2032)
|
LOREAL
| |
| EP3464373B1 | Use Of Anti-Pd-1 Antibody In The Treatment Of Patients With Colorectal Cancer | BRISTOL MYERS SQUIBB CO |
26 Jul, 2022
(Expiration: Jun, 2037)
|
PAJARO
(and 5 more)
| |
| EP3200748B1 | Compositions And Methods For The Treatment And Prophylaxis Of Surgical Site Infections | POLYPID LTD |
26 Jul, 2022
(Expiration: Sep, 2035)
|
SANDOZ
| |
| EP3277270B1 | Compositions And Methods For Treating Anemia | AKEBIA THERAPEUTICS INC |
26 Jul, 2022
(Expiration: Mar, 2036)
|
SANDOZ
| |
| EP3350333B1 | Polynucleotides Containing A Stabilizing Tail Region | MODERNATX INC |
26 Jul, 2022
(Expiration: Sep, 2036)
|
STRAWMAN
| |
| EP3387015B1 | Type Ii Anti-Cd20 Antibody For Reducing Formation Of Anti-Drug Antibodies | F HOFFMANN LA ROCHE AG |
26 Jul, 2022
(Expiration: Dec, 2036)
|
STRAWMAN
| |
| EP2701670B1 | Clear Wet Sprays And Gels | ISP INVESTMENTS LLC |
19 Jul, 2022
(Expiration: Apr, 2032)
|
BASF
| |
| EP3684329B1 | Powder Composition Comprising Hair Direct Dyes | KAO CORP |
19 Jul, 2022
(Expiration: Sep, 2038)
|
LOREAL
| |
| EP3091999B1 | Improved Cell Compositions And Methods For Cancer Therapy | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT CO |
19 Jul, 2022
(Expiration: Jan, 2035)
|
SCRIPT
| |
| EP3689899B8 | Mnd Promoter Chimeric Antigen Receptors | 2SEVENTY BIO INC |
13 Jul, 2022
(Expiration: Apr, 2035)
|
BOULT WADE TENNANT
| |
| EP2593090B1 | C-Met Modulator Pharmaceutical Compositions | EXELIXIS INC |
13 Jul, 2022
(Expiration: Jul, 2031)
|
GENERICS UK
(and 2 more)
| |
| EP3130606B1 | Immunoactivating Antigen-Binding Molecule | CHUGAI PHARMACEUTICAL CO LTD |
13 Jul, 2022
(Expiration: Apr, 2035)
|
J A KEMP
(and 1 more)
| |
| EP3294323B1 | Adeno-Associated For Therapeutic Delivery To Central Nervous System | INDIVIDUAL |
13 Jul, 2022
(Expiration: May, 2036)
|
MAIWALD PATENT UND RECHTSANWALTSGESELLSCHAFT
| |
| EP3012255B1 | Stabilized Crystal Of Tipiracil Hydrochloride, And Crystallization Method For Same | TAIHO PHARMACEUTICAL CO LTD |
13 Jul, 2022
(Expiration: Jun, 2034)
|
STADA ARZNEIMITTEL
| |
| EP3614992B1 | Antidandruff Hair Care Composition Comprising Pyrithione | UNILEVER GLOBAL IP LTD |
13 Jul, 2022
(Expiration: Mar, 2038)
|
THE PROCTER & GAMBLE
| |
| EP3233027B1 | Compositions For Providing Improved Sunscreen Protection | UNILEVER GLOBAL IP LTD |
12 Jul, 2022
(Expiration: Nov, 2035)
|
HENKEL
(and 1 more)
| |
| EP3142661B1 | Method For Suppressing Glucagon Secretion Of An Sglt2 Inhibitor | ASTRAZENECA AB |
06 Jul, 2022
(Expiration: May, 2035)
|
GENERICS UK
| |
| EP3470432B1 | Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist | SANOFI BIOTECHNOLOGY SAS |
06 Jul, 2022
(Expiration: Aug, 2033)
|
NEUEFEIND
(and 3 more)
| |
| EP1976504B1 | Composition Comprising Polyunsaturated Fatty Acids, Proteins And Manganese And/Or Molybden For Improving Membrane Composition | NUTRICIA NV |
06 Jul, 2022
(Expiration: Dec, 2026)
|
SOCIT DES PRODUITS NESTL
| |
| EP3076972B1 | Cancer Treatment With Combination Of Plinabulin And Taxane | BEYONDSPRING INC |
06 Jul, 2022
(Expiration: Oct, 2033)
|
SYNTHON
| |
| EP3100717B1 | Cosmetic | RESTORSEA LLC |
05 Jul, 2022
(Expiration: Jan, 2033)
|
AQUA BIO TECHNOLOGY ASA
| |
| EP3672614B1 | Engineered Extracellular Vesicles And Uses Thereof | CODIAK BIOSCIENCES INC |
05 Jul, 2022
(Expiration: May, 2039)
|
CILOA
| |
| EP3277253B1 | Composition And Process For Shaping Or Altering The Shape Of Hair | LOREAL SA |
05 Jul, 2022
(Expiration: Apr, 2035)
|
HENKEL
| |
| EP3188803B1 | Transparent Multi-Phase System | BEIERSDORF AG |
05 Jul, 2022
(Expiration: Aug, 2035)
|
HENKEL
| |
| EP3179991B1 | Therapeutic Combinations Of A Btk Inhibitor, A Pi3K Inhibitor, A Jak-2 Inhibitor, And/Or A Bcl-2 Inhibitor | ACERTA PHARMA BV |
05 Jul, 2022
(Expiration: Aug, 2035)
|
STADA ARZNEIMITTEL
| |
| EP2985019B1 | Nasal Composition Having Anti-Viral Properties | CHURCH AND DWIGHT CO INC |
01 Jul, 2022
(Expiration: Aug, 2034)
|
PATENTANWALT DIPL ING DIETZE
| |
| EP3564224B1 | Crystalline Form Of Vortioxetine Hydrobromide As Antidepressant Drug | DIPHARMA FRANCIS SRL |
29 Jun, 2022
(Expiration: Jul, 2035)
|
FRKELLY
| |
| EP3656443B1 | Use Of Trl Agonist And Anti-Cd47 Agent To Enhance Phagocytosis Of Cancer Cells | LELAND STANFORD JUNIOR UNIVERSITY |
29 Jun, 2022
(Expiration: Jan, 2036)
|
GENMAB
(and 1 more)
| |
| EP3706796B1 | Exosomes Comprising Rna Therapeutics | EVOX THERAPEUTICS LTD |
29 Jun, 2022
(Expiration: Nov, 2038)
|
STRAWMAN
| |
| EP3664894B1 | Saccharomyces Boulardii For The Treatment Of Mood Disorders | BIOCODEX SAS |
24 Jun, 2022
(Expiration: Aug, 2038)
|
LESAFFRE
| |
| EP3709960B1 | Hair Care Composition | UNILEVER GLOBAL IP LTD |
23 Jun, 2022
(Expiration: Nov, 2038)
|
HENKEL
| |
| EP2892535B1 | Method Of Adjuvant Cancer Treatment | NOVARTIS AG |
22 Jun, 2022
(Expiration: Aug, 2033)
|
GENERICS UK
(and 2 more)
| |
| EP2696704B1 | Process For The Manufacture Of A Powder Containing Lutein | DSM IP ASSETS BV |
21 Jun, 2022
(Expiration: Mar, 2032)
|
BASF
| |
| EP2345668B1 | Sclerostin Epitopes | UCB PHARMA SA |
21 Jun, 2022
(Expiration: Apr, 2026)
|
JAMES POOLE
| |
| EP3600564B1 | Sunscreen Containing Polyglyceryl-10 Stearate And Citronellol | BEIERSDORF AG |
21 Jun, 2022
(Expiration: Mar, 2038)
|
LOREAL
| |
| EP3600565B1 | Sunscreen Containing Polyglyceryl-10 Stearate And Linalool | BEIERSDORF AG |
21 Jun, 2022
(Expiration: Mar, 2038)
|
LOREAL
| |
| EP3437645B1 | Film-Coated Tablet Having High Chemical Stability Of Active Ingredient | INTERCEPT PHARMACEUTICALS INC |
21 Jun, 2022
(Expiration: Mar, 2037)
|
SANDOZ
| |
| EP3700352B1 | Aroma Composition | SYMRISE AG |
20 Jun, 2022
(Expiration: Oct, 2037)
|
FIRMENICH
| |
| EP3033086B1 | Combination Therapy For The Treatment Of Cancer | NOVARTIS AG |
20 Jun, 2022
(Expiration: Aug, 2034)
|
TEVA PHARMACEUTICAL INDUSTRIES
(and 4 more)
| |
| EP3058989B1 | Composition For Forming A Film On Keratin Fibres | WELLA OPERATIONS US LLC |
15 Jun, 2022
(Expiration: Feb, 2036)
|
HENKEL
| |
| EP3621582B1 | Liquid Personal Cleansing Composition | UNILEVER GLOBAL IP LTD |
14 Jun, 2022
(Expiration: Apr, 2038)
|
HENKEL
| |
| EP3056568B1 | Methods For Controlling Blood Pharmacokinetics Of Antibodies | CHUGAI PHARMACEUTICAL CO LTD |
14 Jun, 2022
(Expiration: Mar, 2027)
|
STRAWMAN
(and 1 more)
| |
| EP3035951B1 | Beta-Casein A2 And Blood Glucose Levels | A2 MILK CO LTD |
13 Jun, 2022
(Expiration: Aug, 2034)
|
FONTERRA OPERATIVE GROUP
(and 1 more)
| |
| EP2164447B1 | Polymer-Based Pigment-Bearing Ink | SCHWAN STABILO COSMETICS GMBH AND CO KG |
13 Jun, 2022
(Expiration: May, 2028)
|
HENKEL
| |
| EP3426226B1 | Ophthalmological Composition | URSAPHARM ARZNEIMITTEL GMBH |
09 Jun, 2022
(Expiration: Mar, 2037)
|
PHARMA STULLN
(and 2 more)
| |
| EP3414256B1 | Amine Salt Of Obeticholic Acid | DR REDDYS LABORATORIES LTD |
09 Jun, 2022
(Expiration: Feb, 2037)
|
SOLARA ACTIVE PHARMA SCIENCE
| |
| EP3570845B1 | Sizing Composition For Mineral Wool Based On A Hydrogenated Sugar And Insulating Products Obtained | SAINT GOBAIN ISOVER SA FRANCE |
08 Jun, 2022
(Expiration: Jan, 2038)
|
OWENS CORNING CAPITAL
| |
| EP3082711B1 | Composition Of Pickering Emulsion Comprising Low Amount Of Alcohol | LOREAL SA |
07 Jun, 2022
(Expiration: Dec, 2033)
|
BEIERSDORF
(and 1 more)
| |
| EP3473267B1 | Individualized Vaccines For Cancer | TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAET MAINZ GGMBH |
07 Jun, 2022
(Expiration: May, 2032)
|
WITHERS & ROGERS
| |
| EP3773457B1 | Personal Cleansing Composition | UNILEVER GLOBAL IP LTD |
02 Jun, 2022
(Expiration: Jun, 2039)
|
HENKEL
(and 1 more)
| |
| EP3701795B1 | Microcapsule And Method For Producing The Same | SHIN ETSU CHEMICAL CO LTD |
01 Jun, 2022
(Expiration: Feb, 2040)
|
ARKEMA FRANCE
| |
| EP3076969B1 | Dosage Regimen For An Alpha-Isoform Selective Phosphatidylinositol 3-Kinase Inhibitor | NOVARTIS AG |
01 Jun, 2022
(Expiration: Dec, 2034)
|
ELKINGTON AND FIFE
| |
| EP2841049B1 | Cosmetic Composition Comprising Mattifying Fillers And A Silane | LOREAL SA |
31 May, 2022
(Expiration: Apr, 2033)
|
HENKEL
| |
| EP3498262B1 | Use Of A Gel Of Natural Polysaccharide(S) For The Preparation Of An Injectable Formulation For Treating Joint Degeneration | APTISSEN SA |
31 May, 2022
(Expiration: Jul, 2028)
|
LABORATOIRES VIVACY
| |
| EP3322804B1 | Nuclease-Independent Targeted Gene Editing Platform And Uses Thereof | RUTGERS STATE UNIVERSITY OF NEW JERSEY |
31 May, 2022
(Expiration: Jul, 2036)
|
STRAWMAN
(and 1 more)
| |
| EP3432882B1 | Methods Of Treating Fabry Disease In Patients Having The G9331A Mutation In The Gla Gene | AMICUS THERAPEUTICS INC |
31 May, 2022
(Expiration: Mar, 2037)
|
TEVA PHARMACEUTICAL INDUSTRIES
(and 1 more)
| |
| EP3366283B1 | Direct Compression Formulation And Process | NOVARTIS AG |
30 May, 2022
(Expiration: Jan, 2025)
|
HAMM&WITTKOPP PATENTANWLTE PARTMBB
(and 5 more)
| |
| EP3498734B1 | Combination Of A Pd-1 Antagonist And A Vegfr Inhibitor For Treating Cancer | MERCK SHARP AND DOHME LLC |
27 May, 2022
(Expiration: Feb, 2035)
|
BOULT WADE TENNANT
(and 6 more)
| |
| EP3694477B1 | Topical Products With A Biphasic System | CMED AESTHETICS SRL |
27 May, 2022
(Expiration: Sep, 2038)
|
GPQ
| |
| EP3107575B1 | Methods For Treating Or Preventing Asthma By Administering An Il-4R Antagonist | SANOFI BIOTECHNOLOGY SAS |
25 May, 2022
(Expiration: Feb, 2035)
|
D YOUNG
(and 2 more)
| |
| EP3391890B1 | Posaconazole Intravenous Solution Formulations Stabilized By Substituted Beta-Cyclodextrin | MERCK SHARP AND DOHME LLC |
25 May, 2022
(Expiration: Jun, 2031)
|
GENERICS UK
(and 3 more)
| |
| EP3653223B1 | Device For The Oral Delivery Of Therapeutic Compounds | RANI THERAPEUTICS LLC |
25 May, 2022
(Expiration: Jun, 2032)
|
NOVO NORDISK
| |
| EP2869841B1 | Novel Prime-Boosting Regimens Involving Immunogenic Polypeptides Encoded By Polynucleotides | GLAXOSMITHKLINE BIOLOGICALS SA |
24 May, 2022
(Expiration: Jul, 2033)
|
JANSSEN VACCINES & PREVENTION
| |
| EP3175238B1 | Devices And Kits For Production Of Personalized, Concentrated Human Milk Compositions, And Methods Of Making And Using Same | SOCIETE DES PRODUITS NESTLE SA |
24 May, 2022
(Expiration: Jul, 2035)
|
NUTRICIA
| |
| EP2800469B1 | Compositions And Methods For Lowering Levels Of High-Sensitivity (Hs-Crp) In A Subject | AMARIN PHARMACEUTICALS IRELAND LTD |
23 May, 2022
(Expiration: Jan, 2033)
|
ELKINGTON AND FIFE
(and 1 more)
| |
| EP3725778B1 | Formulations Of Enzalutamide | ASTELLAS PHARMA INC |
18 May, 2022
(Expiration: Sep, 2033)
|
HAMM&WITTKOPP PATENTANWLTE PARTMBB
(and 10 more)
| |
| EP2685958B1 | Dental Ceramic Article, Process Of Production And Use Thereof | 3M INNOVATIVE PROPERTIES CO |
18 May, 2022
(Expiration: Mar, 2032)
|
IVOCLAR VIVADENT
| |
| EP3015477B1 | High-Stability T-Cell Receptor And Preparation Method And Application Thereof | XLIFESC LTD |
18 May, 2022
(Expiration: Jun, 2034)
|
MICHALSKI HTTERMANN & PARTNER PATENTANWLTE MBB
| |
| EP2791160B1 | Modified Nucleoside, Nucleotide, And Nucleic Acid Compositions | MODERNATX INC |
18 May, 2022
(Expiration: Dec, 2032)
|
WUESTHOFF & WUESTHOFF PATENTANWLTE PARTG MBB
(and 9 more)
| |
| EP3225112B1 | Photosensitiser Dispersion And Use Of The Same | TRIOPTOTEC GMBH |
17 May, 2022
(Expiration: Apr, 2036)
|
HENKEL
| |
| EP3638198B1 | Composition For Preventing Hair Loss And Promoting Hair Growth | CAPILLI MED GMBH |
16 May, 2022
(Expiration: Jun, 2038)
|
GER
| |
| EP3664774B1 | Hair Cosmetic | KAO CORP |
12 May, 2022
(Expiration: Jul, 2038)
|
HENKEL
| |
| EP3287139B1 | Nerve Growth Factor Composition And Powder Injection | BEIJING STAIDSON MEDICAL TECHNOLOGY CO LTD |
11 May, 2022
(Expiration: Apr, 2036)
|
DOMP FARMACEUTICI
| |
| EP3573721B1 | Active Agent-Containing Articles That Exhibit Consumer Acceptable Article In-Use Properties | PROCTER AND GAMBLE CO |
11 May, 2022
(Expiration: Jan, 2038)
|
HENKEL
| |
| EP3758685B1 | Capsules With Opacifier | CAPSUGEL BELGIUM NV |
11 May, 2022
(Expiration: May, 2039)
|
MLLER BOR & PARTNER PATENTANWLTE PARTG MBB
| |
| EP3320101B1 | Methods And Pharmaceutical Compositions For Expressing A Polynucleotide Of Interest In The Peripheral Nervous System Of A Subject | COMMISSARIAT A LENERGIE ATOMIQUE CEA |
11 May, 2022
(Expiration: Jul, 2036)
|
STRAWMAN
| |
| EP3185843B1 | Gel Composition And Gel Comprising A Uv Filter | LOREAL SA |
10 May, 2022
(Expiration: Aug, 2035)
|
BEIERSDORF
| |
| EP3149137B1 | Foaming Cleanser | LOREAL SA |
10 May, 2022
(Expiration: May, 2035)
|
HENKEL
| |
| EP3360600B1 | Natural Silicone Replacements For Silicone Fluids In Personal Care Formulations | INOLEX INVESTMENT CORP |
10 May, 2022
(Expiration: Nov, 2032)
|
SCOTT BADER
| |
| EP3692983B1 | Oral Formulations Of Cytidine Analogs And Methods Of Use Thereof | CELGENE CORP |
10 May, 2022
(Expiration: May, 2029)
|
TEVA PHARMACEUTICAL INDUSTRIES
(and 5 more)
| |
| EP3444334B9 | Method For Inducing Cd8+ T Cells | KYOTO UNIVERSITY |
06 May, 2022
(Expiration: Apr, 2037)
|
REINERT
| |
| EP3077005B1 | Composition Comprising A Uridine Source And An Omega-3 Pufa For Improving Coordination, Balance, Grip Strength Or Fine Motor Skills | NUTRICIA NV |
04 May, 2022
(Expiration: Sep, 2034)
|
ABBOTT LABORATORIES
| |
| EP2585075B8 | Methods Of Treatment For Esophageal Inflammation | VIROPHARMA BIOLOGICS LLC |
04 May, 2022
(Expiration: Jun, 2031)
|
DR FALK PHARMA
| |
| EP3720418B1 | Nicotine Tablet | FERTIN PHARMA AS |
04 May, 2022
(Expiration: Dec, 2038)
|
MCNEIL
| |
| EP3423082B1 | Liraglutide In Cardiovascular Conditions | NOVO NORDISK AS |
04 May, 2022
(Expiration: Mar, 2037)
|
STADA ARZNEIMITTEL
(and 4 more)
| |
| EP2817000B1 | Oral Pharmaceutical Compositions Of Dabigatran Etexilate | TOWA PHARMACEUTICAL EUROPE SL |
03 May, 2022
(Expiration: Feb, 2033)
|
AERA
(and 2 more)
| |
| EP3360428B1 | Cohesive Thin Liquids To Promote Safe Swallowing In Dysphagic Patients | SOCIETE DES PRODUITS NESTLE SA |
03 May, 2022
(Expiration: Dec, 2032)
|
FRESENIUS KABI DEUTSCHLAND
(and 1 more)
| |
| EP3626258B1 | Methods And Compositions For Cns Delivery Of Iduronate-2-Sulfatase | SHIRE HUMAN GENETICS THERAPIES INC |
03 May, 2022
(Expiration: Jun, 2031)
|
GREEN CROSS
| |
| EP3122312B1 | Corrosive Ingredient (S) - Containing Compositions Having Reduced Toxicity And Method Of Obtaining | SC JOHNSON AND SON INC |
03 May, 2022
(Expiration: Mar, 2035)
|
HENKEL
| |
| EP3270893B1 | Stable Granules With Low Internal Water Activity | DANISCO US INC |
28 Apr, 2022
(Expiration: Mar, 2036)
|
DSM NUTRITIONAL PRODUCTS
(and 1 more)
| |
| EP2834246B1 | Combination Products With Tyrosine Kinase Inhibitors And Their Use | NOVARTIS AG |
28 Apr, 2022
(Expiration: Apr, 2033)
|
D YOUNG
| |
| EP2723302B1 | Dental Restoration, Method For Production Thereof And Glass Ceramic | FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV |
28 Apr, 2022
(Expiration: Jun, 2032)
|
IVOCLAR VIVADENT
| |
| EP3341015B2 | Enhanced Depletion Of Targeted Cells With Cd47 Blockade And An Immune Costimulatory Agonist | LELAND STANFORD JUNIOR UNIVERSITY |
28 Apr, 2022
(Expiration: Aug, 2036)
|
PFIZER
| |
| EP3679922B1 | Syringe | NOVARTIS AG |
28 Apr, 2022
(Expiration: May, 2033)
|
WESS
(and 2 more)
| |
| EP3194970B1 | Immunogenic Mutant Peptide Screening Platform | F HOFFMANN LA ROCHE AG |
27 Apr, 2022
(Expiration: Sep, 2035)
|
BISCHOF & PARTNER RECHTSANWLTE PARTNERSCHAFTSGESELLSCHAFT MBB
| |
| EP2667856B9 | Medical Device Containing A Cake Composition Comprising Aripiprazole As An Active Ingredient, And A Cake Composition Comprising Aripiprazole As An Active Ingredient | OTSUKA PHARMACEUTICAL CO LTD |
27 Apr, 2022
(Expiration: Jan, 2032)
|
HAMM&WITTKOPP PATENTANWLTE PARTMBB
(and 3 more)
| |
| EP3076967B1 | Novel Methods | INTRA CELLULAR THERAPIES INC |
27 Apr, 2022
(Expiration: Dec, 2034)
|
SANDOZ
| |
| EP3398454B1 | Whey Protein Micelles Against Muscle Atrophy And Sarcopenia | SOCIETE DES PRODUITS NESTLE SA |
21 Apr, 2022
(Expiration: Oct, 2032)
|
NUTRICIA
(and 1 more)
| |
| EP3491929B1 | Ameliorative Effects Of A Whole Coffee Fruit Extract On Age-Related Neurodegenerative Disease | LYTONE ENTERPRISE INC |
21 Apr, 2022
(Expiration: Nov, 2038)
|
VDF FUTURECEUTICALS
| |
| EP3611169B1 | New Gadolinium Chelate Compounds For Use In Magnetic Resonance Imaging | BAYER PHARMA AG |
20 Apr, 2022
(Expiration: May, 2036)
|
DE SIMONE & PARTNERS
| |
| EP2914255B1 | Treatment Or Prevention Of Cardiovascular Events Via The Administration Of A Colchicine Derivative | MURRAY AND POOLE ENTERPRISES LTD |
20 Apr, 2022
(Expiration: Nov, 2033)
|
PHARMASCIENCE
(and 1 more)
| |
| EP3056564B1 | Method For Purification Of Retinal Pigment Epithelial Cells | HEALIOS KK |
20 Apr, 2022
|
STRAWMAN
| |
| EP2166882B1 | Supporting Activities Of Daily Living | NUTRICIA NV |
19 Apr, 2022
(Expiration: Jun, 2028)
|
SOCIT DES PRODUITS NESTL
| |
| EP3298142B1 | Dry Powder Composition Comprising Long-Chain Rna | CUREVAC AG |
14 Apr, 2022
(Expiration: May, 2036)
|
BIONTECH
(and 1 more)
| |
| EP3349720B1 | Biosourced Emollient Composition Comprising Isoparaffins | TOTAL MARKETING SERVICES SA |
14 Apr, 2022
(Expiration: Sep, 2036)
|
CABINET TRIPOZ
| |
| EP3440015B1 | Highly Porous Magnesium Carbonate And Method Of Production Thereof | DISRUPTIVE MATERIALS AB |
14 Apr, 2022
(Expiration: Mar, 2037)
|
OMYA
| |
| EP3297682B1 | Dry Powder Composition Comprising Long-Chain Rna | CUREVAC AG |
13 Apr, 2022
(Expiration: May, 2036)
|
SANOFI
(and 1 more)
| |
| EP3522858B1 | Personal Care Compositions Substantially Free Of Sulfated Surfactants And Containing A Gel Network | PROCTER AND GAMBLE CO |
07 Apr, 2022
(Expiration: Oct, 2037)
|
HENKEL
| |
| EP3434265B1 | Pharmaceutical Composition Containing Rifaximin Alpha & Delta | SANDOZ AG |
06 Apr, 2022
(Expiration: Mar, 2037)
|
ALFRED E TIEFENBACHER
(and 2 more)
| |
| EP2771070B1 | Device For Self-Foaming Oxidation Dyeing, Ready-For-Use Self-Foaming Composition And Method For Dyeing Keratinous Fibres | LOREAL SA |
06 Apr, 2022
(Expiration: Oct, 2032)
|
HENKEL
| |
| EP3002009B1 | Treatment Of Imatinib Resistant Leukemia Using 4-Aminoquinoline-3-Carbonitriles | WYETH LLC |
06 Apr, 2022
(Expiration: May, 2028)
|
SANDOZ
| |
| EP3019619B1 | Compositions Comprising Synthetic Polynucleotides Encoding Crispr Related Proteins And Synthetic Sgrnas And Methods Of Use | MODERNATX INC |
01 Apr, 2022
(Expiration: Jul, 2034)
|
VOSSIUS & PARTNER PATENTANWLTE RECHTSANWLTE MBB
(and 1 more)
| |
| EP3549611B1 | Switch Costimulatory Receptors | UNIVERSITY OF PENNSYLVANIA PENN |
30 Mar, 2022
(Expiration: Jul, 2032)
|
OETKE
| |
| EP3606494B1 | Powder For Cleaning An Internal Body Part And/Or An Implant, Method For Producing Said Type Of Powder And Suitable Uses | FERTON HOLDING SA |
30 Mar, 2022
(Expiration: Apr, 2038)
|
W & H DENTALWERK BRMOOS
| |
| EP3582745B1 | Use Of A Particulate Mineral To Reduce Pollution | IMERTECH SAS |
29 Mar, 2022
(Expiration: Feb, 2038)
|
HENKEL
(and 1 more)
| |
| EP3338779B1 | Tumor Therapeutic Agent | EISAI R&D MANAGEMENT CO LTD |
29 Mar, 2022
(Expiration: Aug, 2036)
|
STADA ARZNEIMITTEL
| |
| EP3043773B1 | Stable Fixed Dose Pharmaceutical Composition Comprising Mometasone And Olopatadine | GLENMARK SPECIALTY SA |
29 Mar, 2022
(Expiration: Sep, 2034)
|
TER MEER STEINMEISTER & PARTNER PATENTANWLTE MBB
| |
| EP3103443B1 | Method For Treating Primary Insomnia | NEURIM PHARMACEUTICALS 1991 LTD |
29 Mar, 2022
(Expiration: Aug, 2022)
|
TEVA PHARMACEUTICAL INDUSTRIES
(and 5 more)
| |
| EP3053580B1 | Method Of Providing Pirfenidone Therapy To A Patient | INTERMUNE INC |
28 Mar, 2022
(Expiration: Dec, 2027)
|
AERA
(and 3 more)
| |
| EP3296395B1 | Multiple Antigen Binding Molecular Fusion, Pharmaceutical Composition, Method For Identifying Linear Epitope, And Method For Preparing Multiple Antigen Binding Molecular Fusion | CHUGAI PHARMACEUTICAL CO LTD |
25 Mar, 2022
(Expiration: May, 2036)
|
JAMES POOLE
| |
| EP3436038B1 | Beta-Caseins And Cognitive Function | A2 MILK CO LTD |
23 Mar, 2022
(Expiration: Mar, 2037)
|
ARLA FOODS AMBA
(and 2 more)
| |
| EP3288532B1 | Polymers For Stabilising Peroxide Compounds | BASF SE |
23 Mar, 2022
(Expiration: Apr, 2036)
|
CLARIANT PRODUKTE DEUTSCHLAND
| |
| EP3105331B1 | Ketohexokinase (Khk) Irna Compositions And Methods Of Use Thereof | ALNYLAM PHARMACEUTICALS INC |
23 Mar, 2022
(Expiration: Feb, 2035)
|
GRNECKER PATENT UND RECHTSANWLTE PARTG MBB
| |
| EP3452012B1 | Nutraceutical Or Pharmaceutical Composition For Use In The Treatment Of Polycystic Ovary Syndrome Or Of Diseases Or Disorders Related Thereto | S&R FARMACEUTICI SPA |
22 Mar, 2022
(Expiration: Apr, 2037)
|
LOLI PHARMA
| |
| EP3401335B1 | Composition Comprising Antibody That Binds To Domain Ii Of Her2 And Acidic Variants Thereof | GENENTECH INC |
22 Mar, 2022
(Expiration: Jan, 2029)
|
POHLMAN
(and 4 more)
| |
| EP3458018B2 | Cosmetic Composition Comprising Anionic Surfactants, Amphoteric Surfac-Tants, Cationic Polymers And Liquid Fatty Substances Chosen From Fatty Alco-Hols And Fatty Esters, And Cosmetic Treatment Process | LOREAL SA |
21 Mar, 2022
(Expiration: May, 2037)
|
HENKEL
| |
| EP3294264B1 | Composition For Keratin Fibers | LOREAL SA |
17 Mar, 2022
(Expiration: May, 2036)
|
KAO GERMANY
(and 1 more)
| |
| EP3342786B1 | Anti-Dll3 Antibody | CHUGAI PHARMACEUTICAL CO LTD |
16 Mar, 2022
(Expiration: Jan, 2031)
|
GUDER
(and 1 more)
| |
| EP3255061B1 | Selective Immunodepletion Of Endogenous Stem Cell Niche For Engraftment | LELAND STANFORD JUNIOR UNIVERSITY |
16 Mar, 2022
(Expiration: Nov, 2027)
|
HOFFMANN EITLE
| |
| EP3610827B1 | Method For The Manufacture Of A Blank And Blank | DEGUDENT GMBH |
16 Mar, 2022
(Expiration: Aug, 2038)
|
IVOCLAR VIVADENT
| |
| EP3113753B1 | Aqueous Oxidizing Composition For Hair | KAO GERMANY GMBH |
16 Mar, 2022
(Expiration: Dec, 2033)
|
LOREAL
| |
| EP3284458B1 | Production Process For Nsaid-Containing Lozenges, Their Compositions, Their Medicinal Use | RECKITT BENCKISER HEALTHCARE UK LTD |
16 Mar, 2022
(Expiration: Feb, 2026)
|
ZBM PATENTS
| |
| EP2658508B1 | Two-Part Hair Colouring Composition | KAO GERMANY GMBH |
15 Mar, 2022
(Expiration: Dec, 2031)
|
HENKEL
| |
| EP3240890B1 | Assessing Retinal Pigment Epithelial Cell Populations | CELL CURE NEUROSCIENCES LTD |
15 Mar, 2022
(Expiration: Dec, 2035)
|
MARGARET DIXON
(and 1 more)
| |
| EP2782584B1 | Natural Combination Hormone Replacement Formulations And Therapies | THERAPEUTICSMD INC |
09 Mar, 2022
(Expiration: Nov, 2032)
|
DR SCHN
(and 2 more)
| |
| EP2695528B1 | Nutritional Composition For Improving Muscle Function And Daily Activity | NUTRICIA NV |
03 Mar, 2022
(Expiration: Jul, 2029)
|
FRESENIUS KABI DEUTSCHLAND
| |
| EP3331921B1 | Inulin Product | RAFFINERIE TIRLEMONTOISE SA |
02 Mar, 2022
(Expiration: Aug, 2036)
|
COSUCRA GROUPE WARCOING
| |
| EP3287140B1 | Nerve Growth Factor Composition And Powder Injection | BEIJING STAIDSON MEDICAL TECHNOLOGY CO LTD |
02 Mar, 2022
(Expiration: Apr, 2036)
|
DOMP FARMACEUTICI
| |
| EP3351261B1 | Combination Medicament Comprising Il-12 And An Agent For Blockade Of T-Cell Inhibitory Molecules For Tumour Therapy | UNIVERSITAET ZUERICH |
02 Mar, 2022
(Expiration: Oct, 2032)
|
KRAUS & WEISERT PATENTANWLTE PARTGMBB
(and 4 more)
| |
| EP3348260B1 | Pharmaceutical Tramadol Composition For Ophthalmic Use | FARMALIDER SA |
02 Mar, 2022
(Expiration: Sep, 2036)
|
STRATAGEM
| |
| EP2915526B1 | Pharmaceutical Compositions Comprising Anagrelide | GALENICUM HEALTH SL |
01 Mar, 2022
(Expiration: Mar, 2035)
|
HAMM&WITTKOPP PATENTANWLTE PARTMBB
| |
| EP3247370B1 | Coniferous Resin For Treating And Preventing Sterile Inflammation | REPOLAR PHARMACEUTICALS OY |
28 Feb, 2022
(Expiration: Jan, 2036)
|
BOCO
| |
| EP2649101B1 | Process Of Preparing A Cross Linked Gel | TEOXANE SA |
28 Feb, 2022
(Expiration: Dec, 2031)
|
PETERREINS
(and 1 more)
| |
| EP2919766B1 | Sustained-Release Dosage Forms Of Ruxolitinib | INCYTE HOLDINGS CORP |
28 Feb, 2022
(Expiration: Nov, 2033)
|
STADA ARZNEIMITTEL
(and 3 more)
| |
| EP3137532B1 | Liquid Triblock Copolymer | INGELL TECHNOLOGIES HOLDING BV |
25 Feb, 2022
(Expiration: Apr, 2035)
|
HOFFMANN EITLE
| |
| EP3226843B1 | Anticancer Compositions | ARAGON PHARMACEUTICALS INC |
25 Feb, 2022
(Expiration: Dec, 2035)
|
TEVA PHARMACEUTICAL INDUSTRIES
| |
| EP3346972B1 | Process For Treating Hair | KAO GERMANY GMBH |
24 Feb, 2022
(Expiration: Mar, 2036)
|
LOREAL
| |
| EP2970456B1 | Methods And Compositions For Delivering Mrna Coded Antibodies | TRANSLATE BIO INC |
21 Feb, 2022
(Expiration: Mar, 2034)
|
EIP
(and 3 more)
| |
| EP3383358B1 | Cleansing Bars | COLGATE PALMOLIVE CO |
19 Feb, 2022
(Expiration: Dec, 2035)
|
CLARIANT PRODUKTE DEUTSCHLAND
| |
| EP3381444B1 | Syringe | NOVARTIS AG |
17 Feb, 2022
(Expiration: Jan, 2033)
|
KEIL & SCHAAFHAUSEN PATENTANWLTE PARTGMBB
(and 2 more)
| |
| EP3458019B1 | Product For The Therapy And Prevention Of Burnout Syndrome Of The Scalp And The Skin | APOMEDICA SAGL |
17 Feb, 2022
(Expiration: Apr, 2037)
|
WILDHACK ANDREAS
| |
| EP3364941B1 | Use Of Glycosides To Increase Hair Mass | LOREAL SA |
16 Feb, 2022
(Expiration: Oct, 2036)
|
HENKEL
| |
| EP3078375B1 | Anti-Fatigue Composition | AJINOMOTO CO INC |
14 Feb, 2022
(Expiration: Oct, 2034)
|
NUTRICIA
| |
| EP2943192B9 | Methods Of Treating Pancreatic Cancer | ABRAXIS BIOSCIENCE LLC |
11 Feb, 2022
(Expiration: Jan, 2034)
|
ACCORD HEALTHCARE
(and 2 more)
| |
| EP3352584B1 | Compositions And Methods For Synthesizing 5'-Capped Rnas | TRILINK BIOTECHNOLOGIES LLC |
11 Feb, 2022
(Expiration: Sep, 2036)
|
COHAUSZ & FLORACK PATENT UND RECHTSANWLTE PARTNERSCHAFTSGESELLSCHAFT MBB
(and 1 more)
| |
| EP3386511B2 | Methods For Treating Huntington'S Disease | PTC THERAPEUTICS |
11 Feb, 2022
|
JAMES POOLE
| |
| EP3253377B1 | Monomethylfumarate Prodrug Compositions | ALKERMES PHARMA IRELAND LTD |
11 Feb, 2022
(Expiration: Mar, 2035)
|
TEVA PHARMACEUTICAL INDUSTRIES
(and 3 more)
| |
| EP3473101B1 | Isoxazoline Compositions And Their Use As Antiparasitics For Felines | INTERVET INTERNATIONAL BV |
11 Feb, 2022
(Expiration: Aug, 2028)
|
VIRBAC
(and 1 more)
| |
| EP3435985B1 | Granulate Formulation Of 5-Methy!-1-Pheny!-2(1H)-Pyridone And Method Of Making The Same | F HOFFMANN LA ROCHE AG |
08 Feb, 2022
(Expiration: Mar, 2037)
|
LEDERER & KELLER PATENTANWLTE PARTNERSCHAFT MBB
| |
| EP3650016B1 | Stabilized Modified Release Vitamin D Formulation And Method Of Administering Same | EIRGEN PHARMA LTD |
07 Feb, 2022
(Expiration: Mar, 2034)
|
DSM NUTRITIONAL PRODUCTS
| |
| EP3331383B1 | Nutritional Compositions And Infant Formulas Comprising Bifidobacterium Animalis Ssp. Lactis And Optionally A Mix Of Oligosaccharides For Inducing A Gut Microbiota Close To The One Of Breast Fed Infants | SOCIETE DES PRODUITS NESTLE SA |
04 Feb, 2022
(Expiration: Aug, 2036)
|
CHR HANSEN
| |
| EP3266456B1 | Combinations Of Liposomal Irinotecan, 5-Fu And Leucovorin For The Treatment Of Pancreatic Cancer | IPSEN BIOPHARM LTD |
04 Feb, 2022
(Expiration: Jun, 2033)
|
GENERICS UK
(and 2 more)
| |
| EP3533792B1 | Crystalline Forms Of An Androgen Receptor Modulator | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH |
04 Feb, 2022
(Expiration: Jun, 2033)
|
GENERICS UK
| |
| EP2713997B1 | Process For Treating Straightened Keratin Fibres | LOREAL SA |
04 Feb, 2022
(Expiration: Jun, 2032)
|
HENKEL
| |
| EP3265570B1 | Retroviral And Lentiviral Vectors | AUTOLUS LTD |
04 Feb, 2022
(Expiration: Mar, 2036)
|
MARGARET DIXON
| |
| EP3267981B1 | Transdermal Therapeutic System With An Overtape Comprising Two Adhesive Layers | LUYE PHARMA AG |
03 Feb, 2022
(Expiration: Mar, 2036)
|
LTS LOHMANN THERAPIE SYSTEME
| |
| EP3506884B1 | Drug Delivery Compositions And Uses Thereof | DANA FARBER CANCER INSTITUTE INC |
02 Feb, 2022
(Expiration: Aug, 2037)
|
PATENT BOUTIQUE
| |
| EP2836223B2 | Probiotic Bacteria | SKINBIOTHERAPEUTICS PLC |
28 Jan, 2022
(Expiration: Mar, 2033)
|
CABINET BECKER ET ASSOCIES
| |
| EP2919796B1 | Use Of Akkermansia For Treating Metabolic Disorders | UNIVERSITE CATHOLIQUE DE LOUVAIN UCL |
28 Jan, 2022
(Expiration: Nov, 2033)
|
STRAWMAN
| |
| EP3536310B1 | Syringe | NOVARTIS AG |
28 Jan, 2022
(Expiration: May, 2033)
|
WESS
(and 2 more)
| |
| EP2484383B1 | Method For Improving The Aqueous Solubility Of Poorly-Soluble Substances | SANGI CO LTD |
27 Jan, 2022
(Expiration: Sep, 2030)
|
OMYA
| |
| EP2887961B1 | Nep Inhibitors For Treating Diseases Characterized By Atrial Enlargement Or Remodeling | NOVARTIS AG |
27 Jan, 2022
(Expiration: Aug, 2033)
|
TEVA PHARMACEUTICAL INDUSTRIES
(and 5 more)
| |
| EP3294326B1 | Prime-Boost Regimens Involving Administration Of At Least One Mrna Construct | CUREVAC AG |
21 Jan, 2022
(Expiration: May, 2036)
|
BIONTECH
| |
| EP2819669B1 | Novel Propellant-Gas-Containing Tiotropium Formulation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
21 Jan, 2022
(Expiration: Feb, 2033)
|
HGF
| |
| EP3541387B1 | Dose And Regimen For Hdm2-P53 Interaction Inhibitors | NOVARTIS AG |
20 Jan, 2022
(Expiration: Nov, 2037)
|
STRAWMAN
(and 1 more)
| |
| EP3134065B1 | Composition In The Form Of Nano- Or Micro- Emulsion | LOREAL SA |
17 Jan, 2022
(Expiration: Mar, 2035)
|
HENKEL
| |
| EP2478907B1 | Methods And Compositions For Treating Cancer | JANSSEN ONCOLOGY INC |
14 Jan, 2022
(Expiration: Aug, 2027)
|
GLENMARK PHARMACEUTICALS EUROPE
(and 21 more)
| |
| EP3148574B1 | Purified Compositions Of Ivig And Kh Proteins For Modulating Lymphocytes And Treating Hepatitis B Virus | RARE ANTIBODY ANTIGEN SUPPLY INC |
14 Jan, 2022
(Expiration: May, 2035)
|
HOFFMAN EITLE PATENT UND RECHTSANWLTE PARTNERSCHAFTSGESELLSCHAFT MBB
| |
| EP2861073B1 | Soluble Estradiol Capsule For Vaginal Insertion | THERAPEUTICSMD INC |
14 Jan, 2022
(Expiration: Jun, 2033)
|
RIECK
| |
| EP3381942B1 | A Method For Treating Melanoma Using A Herpes Simplex Virus And An Immune Checkpoint Inhibitor | AMGEN INC |
13 Jan, 2022
(Expiration: Aug, 2033)
|
HOFFMAN EITLE PATENT UND RECHTSANWLTE PARTNERSCHAFTSGESELLSCHAFT MBB
| |
| EP3656765B1 | Salts Or Co-Crystals Of 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)-Phenol | GRUENENTHAL GMBH |
13 Jan, 2022
(Expiration: Jul, 2031)
|
INSUD PHARMA SL
(and 5 more)
| |
| EP2863895B1 | Tablet Formulation Comprising A Peptide And A Delivery Agent | NOVO NORDISK AS |
13 Jan, 2022
(Expiration: Jun, 2033)
|
MERCK SHARP & DOHME
(and 6 more)
| |
| EP3592391B1 | Pharmaceutical Composition Comprising Selexipag | ACTELION PHARMACEUTICALS LTD |
12 Jan, 2022
(Expiration: Mar, 2038)
|
TEVA PHARMACEUTICAL INDUSTRIES
| |
| EP2994162B1 | Vaccine For Pcv2 And Mycoplasma | PHARMGATE BIOLOGICS INC |
07 Jan, 2022
(Expiration: May, 2034)
|
BOEHRINGER INGELHEIM VETMEDICA
| |
| EP3137497B1 | Aav Vectors For Retinal And Cns Gene Therapy | GENZYME CORP |
07 Jan, 2022
(Expiration: May, 2035)
|
EUROPEAN OPPOSITIONS
| |
| EP2836581B1 | A Highly Efficient And Convenient Form Of Microfibrous Cellulose | CP KELCO US INC |
07 Jan, 2022
(Expiration: Feb, 2033)
|
RHODIA OPERATIONS
| |
| EP3166636B1 | Psgl-1 Modulators And Uses Thereof | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE |
06 Jan, 2022
(Expiration: Jul, 2035)
|
REGIMBEAU
| |
| EP3431475B1 | Solid Forms Of A Selective Cdk4/6 Inhibitor | PFIZER INC |
06 Jan, 2022
(Expiration: Feb, 2034)
|
TEVA PHARMACEUTICAL INDUSTRIES
(and 3 more)
| |
| EP3320891B1 | Hair Cosmetic | KAO CORP |
05 Jan, 2022
(Expiration: Jul, 2036)
|
HENKEL
| |
| EP3063159B1 | Process For Purification Of A Neutral Human Milk Oligosaccharide Using Simulated Moving Bed Chromatography | JENNEWEIN BIOTECHNOLOGIE GMBH |
04 Jan, 2022
(Expiration: Oct, 2034)
|
FRIESLANDCAMPINA NEDERLAND
|